Biotech Boom Drives Lyophilisation
Contributor:
Andrea Charles
Posted: 08/05/2010 12:00:00 AM EDT | 0
Posted: 08/05/2010 12:00:00 AM EDT | 0
|
Biological shift
A growing biotechnology pipeline is fuelling the demand for lyophilisation technologies, and drug companies are looking to partner with contract manufacturing organisations (CMOs) which can assist them with lyophilising their increasing biological product range.
In a recent interview with Pharma IQ, Tim Nicholls, director at eXmoor pharma concepts said: ...
-
What next for PIM and Lifecycle Management? -
eCTD Rises in Popularity Across Europe -
Applying Biopharmaceutical Nanotechnology to Diagnostics, Drug Discovery and Drug Delivery -
Would ASEAN Accept Data and Reviews that Cross Borders? -
An ABC Strategy for Anti-Corruption and Compliance Best Practice -
How Lean Can Bring Real Benefits to Innovation in Pharmaceutical Research -
India Looks to a Future in Clinical Trials -
Pharmacovigilance in Asia: Will China One Day Take the Lead? -
Paediatric Investigation Plans: Burden or boost? -
From Supply Chain to Value Chain: The Leadership Challenge
* = required.
Not a member yet? Sign up
Events of Interest
-
Overcoming Common Lyophilization Scale-up Issues
November 15, 2011
Register Now -
Outsourcing: Challenging the Project Management System at Your Organisation
July 19, 2011
Register Now -
Global HTA and CER Forum 2011
August 31, 2011
Register Now -
Adverse Event Reporting Online Training Course 2011
August 3, 2011
Register Now




Not a member? Sign Up
Reasons for Joining
Address your challenges through knowledge sharing with peers from our global network of specialists.
Benchmark your business initiatives with the who's who in the field.
Hear from industry pioneers how to maximize ROI in today's challenging economy.
And best of all It's FREE!